Among patients with advanced and progressive chronic kidney disease, the discontinuation of RAS inhibitors was not associated with a significant between-group difference in the long-term rate of decrease in the eGFR. (Funded by the National Institute for Health Research and the Medical Research Coun …
This week, we will discuss another IgA Nephropathy trial – Sparsentan this time. A dual endothelin antagonist and angiotensin receptor antagonist.
PubMed® comprises more than 36 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full text…
Episode 048: TESTING is the latest IgA nephropathy trial and it is the comeback kid of nephrology trials. From a trial that was halted because…
To estimate the cost-effectiveness of Nefecon in addition to the best supportive care (BSC) vs BSC in a hypothetical cohort of commercially insured adult patients…
This week, we will discuss NEFIGARD, the trial of a targeted release steroid. It reduces proteinuria in IgA nephropathy – should it upstage humble prednisone?
This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a…
This week, we will discuss NEFIGARD, the trial of a targeted release steroid. It reduces proteinuria in IgA nephropathy – should it upstage humble prednisone?
Episode 048: TESTING is the latest IgA nephropathy trial and it is the comeback kid of nephrology trials. From a trial that was halted because…
To estimate the cost-effectiveness of Nefecon in addition to the best supportive care (BSC) vs BSC in a hypothetical cohort of commercially insured adult patients…
